Skip to content

Therapeutic Effect of Intravascular Laser Irradiation of Blood

The Investigation of Therapeutic Effect and Molecular Mechanism After Intravascular Laser Irradiation of Blood

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03724799
Enrollment
12
Registered
2018-10-30
Start date
2018-11-14
Completion date
2019-09-30
Last updated
2018-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low-Level Laser Therapy

Brief summary

The investigators' previous studies results showed that the non-invasive treatment effects of low-energy lasers with the period of 5 consecutive days, could significantly improve the local function of static and dynamic motion stability of the lower extremities (p\<0.0001) among the participants with lower limb periostitis. Therefore, investigators would like to further understand the treatment effect of intravascular low-energy laser on the central nervous system disorders. It is hoped that with this study, investigators can better understand how to use intravenous laser therapy to help those participants improve their ability of self-care and functional recovery.

Interventions

DEVICEIntravascular laser irradiation of blood for the patients with cerebral infarction

Intravenous low level therapy has been a variety of applications in many different areas of medicine with a growing interest. It possesses laser specific biomodulation, analgesic, spasmolytic and even sedative effects among many other.

Sponsors

Tri-Service General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

Healthy controls Inclusion Criteria: * Written informed consent that is consistent with ICH-GCP guidelines(The International Conference on Harmonisation's Guideline for Good Clinical Practice). * Age ≥ 18 years and ≤80 years of age. * Body weight ≥40 kg

Exclusion criteria

* Subjects with cranial metallic implants, cardiac pacemakers or claustrophobia. * Previous diagnosis of stroke or dementia * Significant history of depression * History of symptomatic stroke * History of seizures * History or presence of any other major neurological disease * Myocardial infarction within prior 6 months. * Known presence of any malignancy * Patients with bleeding tendency or coagulation profile abnormalities * Have a serious infection or other serious medical illness that requires treatment and/or hospitalization within 90 days before study entry. * Have received any of the following within 6 months of study entry: systemic corticosteroids; chemotherapy or radiation; erythropoietin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or growth hormone; drugs that affect the immune system including thalidomide, interleukins, interferons, or other cytokines; anabolic steroids at high levels; or any experimental agent, unless allowed otherwise by the researchers. * Participation in any other investigational trial within 4 weeks of initial screening and within 7 weeks of study entry * Contraindications to head CT, MRI, or SPECT * Pregnant or lactating * Botox treatment to the involved arm within three months of enrollment * Subjects with conscious disturbance or moderate to severe aphasia Stroke group: Inclusion Criteria: * Written informed consent that is consistent with ICH-GCP guidelines. * Age ≥ 18 years and ≤80 years of age. Substantial unilateral motor impairment * At least 6 months post thromboembolic ischemic stroke in subcortical region of MCA or lenticulostriate artery with or without cortical involvement. * Between 6 and 24 months post-stroke, and having a motor or sensory neurological deficit * No significant further improvement with physical therapy/rehabilitation * Able and willing to undergo computed tomography (CT), magnetic resonance imaging (MRI), and single photon emission tomography (SPECT) scans of the head

Design outcomes

Primary

MeasureTime frameDescription
microcirculatory function of the skin12 daysLaser Doppler Flowmetry is reliable for assessing microcirculatory status.

Contacts

Primary ContactCheng-Chiang Chang, MD. PhD.
doc31146@gmail.com886-2- 87923311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026